advertisement
Abstract #23517 Published in IGR 11-2
The effect of prostaglandin analogs and prostamide on central corneal thickness
Hatanaka M; Vessani RM; Elias IR; Morita C; Susanna Jr RJournal of Ocular Pharmacology and Therapeutics 2009; 25: 51-53
OBJECTIVE: The aim of this study was to verify the influence of prostaglandin analogs and prostamide on central corneal thickness (CCT). METHODS: A prospective analysis was done of CCT in glautomatous patients submitted to monotherapy with prostaglandin analogs (latanoprost 0.005% or travoprost 0.004%) or prostamide (bimatoprost 0.03%) during an 8-week period. A control group of patients without any ocular medication was also evaluated. CCT measurements were performed with a commercially available ultrasound pachymeter. A total of 73 patients were included in this study. Mean age was 68.5 (plus or minus) 9.2 (range, 48-85) years old. RESULTS: A statistically significant reduction in CCT was observed in all groups, except the control group (n = 21): Bimatoprost 0.03% group (n = 21): 544.41 (plus or minus) 35.4 vs. 540.35 (plus or minus) 35.9 μm (P = 0.039); travoprost 0.004% group (n = 17): 538.47 (plus or minus) 32.0 vs. 532.25 (plus or minus) 30.4 μm (P = 0.009); latanoprost 0.005% group (n = 14): 548.57 (plus or minus) 32.4 vs. 543.88 (plus or minus) 35.6 μm (P = 0.036). CONCLUSION: Topical therapy with prostaglandin analogs and bimatoprost is associated with CCT reduction over a period of at least 8 weeks.
M. Hatanaka. Department of Ophthalmology, University of Sao Paulo, Av. Dr. Eneas Carvalho de Aguiar, 255, Sao Paulo 05401-000, Brazil. info@centroavancado.net
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
2.2 Cornea (Part of: 2 Anatomical structures in glaucoma)